Stressor: 642

Title

Chemical name selected from established chemical ontologies or, depending on the information available, this could also refer to chemical categories (i.e., groups of chemicals with defined structural features known to trigger the MIE).  It can also include non-chemical prototypical stressors such as genetic or environmental factors. More help

Saracatinib

Stressor Overview

A structured data field that can be used to annotate an AOP with standardized terms identifying prototypical stressors known to trigger the MIE(s)/AOP. More help

AOPs Including This Stressor

This table is automatically generated and lists the AOPs associated with this prototypical stressor. More help

Chemical Table

A list of chemicals associated with a prototypical stressor. More help
User term DTXID Preferred name Casrn jchem_inchi_key indigo_inchi_key
Saracatinib DTXSID90191355 Saracatinib 379231-04-6 OUKYUETWWIPKQR-UHFFFAOYSA-N OUKYUETWWIPKQR-UHFFFAOYSA-N

References

List of the literature that was cited for this prototypical stressor. More help

Musumeci, F., Schenone, S., Brullo, C., & Botta, M. (2012). An update on dual Src/Abl inhibitors. Future Medicinal Chemistry, 4(6), 799–822. https://doi.org/10.4155/fmc.12.29

Hennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., Lambert-Van Der Brempt, C., Morgentin, R., Norman, R. A., Olivier, A., Otterbein, L., Plé, P. A., Warin, N., & Costello, G. (2006). N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Journal of Medicinal Chemistry, 49(22), 6465–6488. https://doi.org/10.1021/jm060434q

Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., Elvin, P., Boyer, B., Carragher, N., Plé, P. A., Bermingham, A., Holdgate, G. A., Ward, W. H. J., Hennequin, L. F., Davies, B. R., & Costello, G. F. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology, 3(3), 248–261. https://doi.org/10.1016/j.molonc.2009.01.002

Kaufman, A. C., Salazar, S. V, Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., Van Dyck, C. H., Nygaard, H. B., Strittmatter, S. M., & Author, A. N. (2015). Fyn Inhibition Rescues Established Memory and Synapse Loss in Alzheimer Mice HHS Public Access Author manuscript. Ann Neurol, 77(6), 953–971. https://doi.org/10.1002/ana.24394